The biopharmaceutical sector is poised for a significant increase in merger and acquisition (M&A) activity in 2026, driven by a buoyant market and enhanced financial capabilities among leading companies. A report released by EY during the 43rd Annual J.P. Morgan Healthcare Conference indicates that the capital earmarked for M&A by the top 25 biopharma firms has risen to $1.6 trillion, up from $1.3 trillion a year earlier. This surge in financial resources is projected to lead to a notable rise in both the number and value of M&A transactions, although initial public offerings (IPOs) are expected to remain sluggish.
In the year leading up to November 30, 2025, the total value of biopharma M&A deals soared by approximately 66%, reaching $149 billion, compared to $90 billion the previous year. This increase occurred despite a 9% decline in the volume of deals, which fell from 94 in 2024 to 76. Adding to this financial capacity, the potential for M&A in artificial intelligence (AI)-enabled applications and diagnostics further boosts the total to $2.1 trillion.
Strong Industry Fundamentals Support M&A Growth
According to Subin Baral, EY’s global life sciences deals leader, the fundamentals of the industry remain robust. He noted that a rapid pace of innovation, particularly in areas such as neuroscience and oncology, is driving biopharma companies to capitalize on new opportunities. In 2025, neuroscience M&A spending reached $83 billion, placing it second only to oncology, which accounted for $146 billion.
Baral commented, “We expect the surge to continue into 2026. The industry fundamentals continue to remain strong.” He emphasized that the focus for companies will be on executing deals that create value and bring new medicines to market promptly.
Recent M&A announcements have already influenced stock movements in the sector. For instance, shares of Ventyx Biosciences surged nearly 37% following a deal in which Eli Lilly agreed to acquire the company for approximately $13.73 per share. Similarly, Revolution Medicines saw its stock price increase by nearly 29% amid speculation of a potential acquisition by AbbVie, despite the latter denying such reports.
Challenges Persist for IPO Market
Despite the optimism surrounding M&A, the IPO market remains lackluster. EY reported that biopharmaceutical IPOs totaled $1.755 billion through September 30, 2025, a significant drop of 56% from the $3.995 billion raised in all of 2024. Baral indicated that while there are signs of potential improvement, the overall sentiment remains cautious.
Two companies, Insilico Medicines and Aktis Oncology, have recently made headlines with their IPO plans. Insilico Medicines raised approximately $292.3 million on the Hong Kong Exchange at the end of December 2025, while Aktis Oncology is anticipated to generate between $188.4 million and $211.95 million in a planned offering. The proceeds from Aktis’ IPO are earmarked for advancing clinical trials of its targeted radiopharmaceuticals for cancer treatment.
The ongoing “patent cliff” faced by many biopharma companies is also influencing M&A strategies. With blockbuster drugs losing patent protection, the industry is under pressure to recoup lost sales. According to a recent report, the top 20 drugs approaching patent expiration between 2026 and 2029 accounted for a staggering $176.442 billion in sales in 2024.
Baral highlighted that the emergence of China as a biopharma innovator is reshaping the landscape. The country accounted for 34% of total alliance investment from U.S. and European biopharmaceuticals in 2025, a significant increase from 4% in 2020. The appeal lies in China’s efficient R&D pathways, which present opportunities for companies looking to diversify their portfolios.
In addition, the increasing integration of AI into the biopharma sector is expected to enhance the efficiency of M&A transactions. The potential value of life sciences deals focused on AI technology platforms surged from about $1 billion in 2014 to $49.6 billion in 2025.
While the landscape for biopharma M&A appears promising, the IPO market faces significant challenges. Investors are currently favoring more established companies with de-risked drug candidates, particularly in established therapeutic areas such as cancer. As the industry navigates these complexities, the focus will remain on strategic mergers and acquisitions as a means to foster growth and innovation.
